UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
------
LYNX THERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Name of Issuer)
Common
--------------------------------------------------------------------------------
(Title of Class of Securities)
551812407
----------------------------------
(CUSIP Number)
12/31/02
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/x/ Rule 13d-1(b)
/ / Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 551812407
---------
-------------------------------------------------------------------------------
(1) Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Hambrecht & Quist Capital Management 943021090
-------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
-------------------------------------------------------------------------------
(3) SEC Use Only
-------------------------------------------------------------------------------
(4) Citizenship or Place of Organization
Delaware Corp.
-------------------------------------------------------------------------------
Number of Shares (5) Sole Voting Power
Beneficially 283,570
Owned by --------------------------------------------------
Each Reporting (6) Shared Voting Power
Person With:
--------------------------------------------------
(7) Sole Dispositive Power
--------------------------------------------------
(8) Shared Dispositive Power
-------------------------------------------------------------------------------
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
1,700,000
-------------------------------------------------------------------------------
(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) / /
-------------------------------------------------------------------------------
(11) Percent of Class Represented by Amount in Row (9)
6.09%
-------------------------------------------------------------------------------
(12) Type of Reporting Person (See Instructions)
IA
-------------------------------------------------------------------------------
SCHEDULE 13G EXHIBIT
ITEM 1.
Lynx Therapeutics, Inc.
25861 Industrial Blvd.
Hayward, CA 94545
ITEM 2.
Hambrecht & Quist Capital Management LLC
30 Rowes Wharf - 4th Floor
Boston, MA 02110-3328
(Delaware corporation)
Common stock
CUSIP: 551812407
ITEM 3.
(e) Investment Adviser
ITEM 4.
Hambrecht & Quist Capital Management LLC ("HQCM") disclaims any beneficial
interest in the shares reported in this Schedule 13G. Moreover, HQCM is of
the view that the client accounts that it manages are not acting as a "group"
for purposes of Section 13(d) under the Securities and Exchange Act of 1934
(the "1934 Act") and that it and such clients are not otherwise required to
attribute to each other the "beneficial ownership" of securities
"beneficially owned" under Rule 13d-3 promulgated under the 1934 Act.
Therefore, HQCM is of the view that the shares held in such accounts should
not be aggregated for purposes of Section 13(d). However, HQCM is making this
filing on a voluntary basis as if all the shares are beneficially owned by
HQCM on a joint basis.
283,570 shares of Common stock beneficially owned 6.09% of Common 283,570
sole voting power (i) and sole dispositive power (iii)
ITEM 5.
N/A
ITEM 6.
N/A
ITEM 7.
N/A
ITEM 8.
N/A
ITEM 9.
N/A
E-1
ITEM 10.
By signing below I certify that, to the best of my knowledge and belief, the
securities referred to above were acquired in the ordinary course of business
and were not acquired for the purpose of and do not have the effect of
changing or influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any transaction having
such purposes or effect.
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: 2/25/03
Signature:
----------------------------------------
Name/Title: Kim Carroll, Vice President
Hambrecht & Quist Capital Management LLC
E-2